Active Stocks
Tue May 21 2024 15:59:52
  1. Tata Steel share price
  2. 174.30 3.81%
  1. NTPC share price
  2. 371.90 1.50%
  1. Power Grid Corporation Of India share price
  2. 325.45 2.71%
  1. Tata Motors share price
  2. 951.15 -0.19%
  1. State Bank Of India share price
  2. 830.55 1.18%
Business News/ Markets / Ipo/  First SME IPO of 2023 scheduled to open on February 21 at a fixed price of 27

First SME IPO of 2023 scheduled to open on February 21 at a fixed price of ₹27

From February 21st to February 24th, 2023, Patron EXIM Ltd. wants to conduct an Initial Public Offering (IPO).

Pharma SME consistently doubles revenue every 2 quarters and plans to go Public on 21st February at a fixed price of ₹27.Premium
Pharma SME consistently doubles revenue every 2 quarters and plans to go Public on 21st February at a fixed price of 27.

From February 21st to February 24th, 2023, Patron EXIM Ltd. wants to conduct an Initial Public Offering (IPO). The company, which originated in 1982 as a partnership and later transformed into a limited liability company, will be listed on the BSE.

Patron Exim is a member of a large group of businesses that also includes Cedac Medicorp, Evoque Remedies, Earum Pharmaceuticals, Auxilia Pharmaceuticals, Madrid Diamonds, Atlantis Exim, N G Overseas, and many others. The Group of Companies operates primarily in the pharmaceutical, chemical industries and adjacent industries.

Patron EXIM acquires, manufactures, and distributes surgical and non-surgical products, active pharmaceutical ingredients (APIs), drug intermediates, Medical Pharmaceutical Chemicals, bio-chemical product preparation & formulation, and other products for the international and domestic markets. In addition to 20 years of business experience and a vast array of certifications, the company has a diversified product portfolio, seasoned promoters, and a high level of client satisfaction in order to conduct business efficiently in the International markets.

The majority of their customers are direct suppliers to corporations such as Johnson & Johnson, Dr. Reddy, Cipla, Sun Pharma, Torrent Pharmaceuticals Ltd, Pidilite Industries, Akzo Nobel India, British Paints India Pvt. Ltd., Vaseline, etc.

The Fixed Price Offering will be priced at 27 per share, with an issue size of  16.69 Crores. The proceeds from the public offering will be used for operating capital, general company objectives, and public issue costs. The initial public offering was priced at 27 per equity share, based on a Face Value of 10 and a NAV of 17.

Patron Exim also takes up government contracts & had carried out business during Covid-19. They supplied raw materials to all of the major Indian pharmaceutical companies and are on the government's list of important businesses. During Covid -19, i.e., throughout the lockdown period, they had conducted commercial operations without incident.

Although Patron Exim had generated a substantial amount of income during the Covid-19, the company's profit margins were unable to withstand the competition. Instead of purchasing and selling the goods, the company decided to act as a commission agent and charge the commission, which resulted in excellent financial returns with a net profit increase of 6500% from Rs. 2.2 lakhs in March 2020 to Rs. 2.28 crores in November 2022, and revenue nearly doubling every two quarters from Rs. 5 crores in March 2022 to Rs. 10.54 crores in November 2022.

The company's P/E ratio is 11.25, which is lower than the industry average of 22.73, and its EPS is 5.84, which is expanding exponentially every quarter. The RoNW is 8.94% and the company's net worth has increased by 525 percent from Rs. 2.6 crores in 2020 to Rs. 16.25 crores in 2022. Given the decreased P/E ratio and rising EPS, Networth, and RoNW, the company exhibits strong and consistent growth, which, when combined with its industry, makes it recession-proof. Moving to the commissioning model raised profit margins by 70% and decreased dead inventory/stagnant inventory time, both of which are essential for any trading and pharma-related organisation.

The company had always remained profitable irrespective of the situation and after they had switched to the commissioning model we could see a massive jump in EBITDA in 2022, i.e of 142% from 2021 to 2022. If a company has a higher EBITDA margin, that means that its operating expenses are lower in relation to total revenue, which ultimately increases the PAT even if the revenue stays stagnant or declines. 

Patron Exim has a pending order book worth 23 crores that is likely to be delivered during the following quarter, indicating a lucrative quarter is in the works. Also, the company has secured new distributors in Canada and Eastern Europe, which will ultimately increase the company's export reach in the coming years.

Nikhil Bhatt (SEBI Registered) of Investment Point rates Patron Exim's IPO as "Subscribe for Long Term."

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed - it's all here, just a click away! Login Now!

Vipul Das
Vipul Das is a Digital Business Content Producer at Livemint. He previously worked for (OneIndia News) and has over 5 years of expertise in the finance and business sector. Stocks, mutual funds, personal finance, tax, and banking are among his specialties, and he is a professional in industry research and business reporting. He received his bachelor's degree from Dr. CV Raman University and also have completed Diploma in Journalism and Mass Communication (DJMC).
Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 18 Feb 2023, 07:14 PM IST
Next Story footLogo
Recommended For You

Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

Let’s get started